Kyle McFarland

573 total citations
8 papers, 400 citations indexed

About

Kyle McFarland is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Kyle McFarland has authored 8 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 2 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Kyle McFarland's work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Kyle McFarland is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Kyle McFarland collaborates with scholars based in United States. Kyle McFarland's co-authors include John F. DiPersio, Michael P. Rettig, Keith Stockerl‐Goldstein, Peter Westervelt, Ravi Vij, Geoffrey L. Uy, Kathryn Trinkaus, Amanda F. Cashen, Camille N. Abboud and Lindsay Hladnik and has published in prestigious journals such as Blood and Leukemia & lymphoma.

In The Last Decade

Kyle McFarland

8 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle McFarland United States	6	258	188	159	103	61	8	400
Hollie Devine United States	7	343 1.3×	146 0.8×	131 0.8×	257 2.5×	50 0.8×	9	524
M Martín-Ayuso Spain	9	164 0.6×	66 0.4×	127 0.8×	110 1.1×	54 0.9×	10	280
Monique Terwijn Netherlands	8	313 1.2×	109 0.6×	120 0.8×	138 1.3×	62 1.0×	16	412
Émilie Cayssials France	10	187 0.7×	103 0.5×	148 0.9×	68 0.7×	153 2.5×	25	388
Mélanie Pannetier France	3	161 0.6×	82 0.4×	75 0.5×	157 1.5×	50 0.8×	6	284
Catherine Spier United States	8	169 0.7×	168 0.9×	150 0.9×	109 1.1×	57 0.9×	10	384
Fransien de Boer Netherlands	7	157 0.6×	92 0.5×	115 0.7×	89 0.9×	130 2.1×	14	324
Yoshiaki Kuroda Japan	12	222 0.9×	161 0.9×	71 0.4×	204 2.0×	51 0.8×	36	403
Daniela Hernandez United States	10	209 0.8×	47 0.3×	191 1.2×	138 1.3×	53 0.9×	16	447
Shihong Yang Australia	10	220 0.9×	180 1.0×	254 1.6×	105 1.0×	22 0.4×	21	403

Countries citing papers authored by Kyle McFarland

Since Specialization

Citations

This map shows the geographic impact of Kyle McFarland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle McFarland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle McFarland more than expected).

Fields of papers citing papers by Kyle McFarland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle McFarland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle McFarland. The network helps show where Kyle McFarland may publish in the future.

Co-authorship network of co-authors of Kyle McFarland

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle McFarland. A scholar is included among the top collaborators of Kyle McFarland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle McFarland. Kyle McFarland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Rettig, Michael P., Theresa Fletcher, Julie Ritchey, et al.. (2021). A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leukemia & lymphoma. 62(6). 1441–1449. 5 indexed citations

2.

Schroeder, Mark A., Michael P. Rettig, Stephanie Christ, et al.. (2017). Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 129(19). 2680–2692. 59 indexed citations

3.

Uy, Geoffrey L., Michael P. Rettig, Ibraheem Motabi, et al.. (2012). A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119(17). 3917–3924. 310 indexed citations

4.

Rettig, Michael P., et al.. (2010). Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor. Blood. 116(21). 2261–2261. 3 indexed citations

5.

Uy, Geoffrey L., Michael P. Rettig, Kyle McFarland, et al.. (2009). A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. Blood. 114(22). 787–787. 5 indexed citations

6.

Rettig, Michael P., Kyle McFarland, Julie Ritchey, et al.. (2009). Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.. Blood. 114(22). 32–32. 5 indexed citations

7.

Uy, Geoffrey L., Michael P. Rettig, Kyle McFarland, et al.. (2008). Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. Blood. 112(11). 1944–1944. 7 indexed citations

8.

Rettig, Michael P., William D. Shannon, Julie Ritchey, et al.. (2008). Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor. Blood. 112(11). 3476–3476. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact